Cannabinoids are a natural family chemicals that are located in the cannabis plant (cannabis sativa). They consist of two chief cannabinoids and these consist of Tetrahydrocannabinol and CBD. Tetrahydrocannabinol (THC) is the primary psychoactive ingredient in cannabis and it is said to give you the high feeling when induced into the endocannabinoid system. Cannabidiol (CBD) is the other main active ingredient in cannabis and it is said to hold neuroprotective and anti inflammatory mechanisms.
The endocannabinoid system is the place throughout the body where cannabinoid receptors, mainly 1 and 2, allow cannabinoids to bind and work in the body. Plant cannabinoids, synthetic cannabinoids and ofcourse natural endocannabinoids are the main cannabinoids that humans deal with. Endogenous cannabinoids and naturally occurring cannabinoids in the marijuana plant are said to have neuroprotective effects arising from brain injury.
This paper will look into a type of cannabinoid that can inhibit glutamatergic synaptic transmission in rats brains. This basically means that the researchers here will find out if a specific cannabinoid can act as a neuroprotective agent in the brains of rats.
It has been seen in clinical trials that the triggering of cannabinoid receptors induces a synaptic boost in the blood brain barrier of animals. Researchers here tested cannabinoid receptor agonists for impacts on inticing neuronal signalling between cultured rat hippocampal neurons. By decreasing the extracellular concentration in the brain, movement increases in intracellular concentrations conclude in increase activity at neuronal sites as conjured by microfluorimetry. This all basically means that cannabinoids may be a sound drug to induce in decaying brains.
Cannabinoids seem to have the ability to reboost damaged neurons, however this is not fully understood or fully described. More research is needed to take place in order to fully know if this is the case and if so, why does it happen?. More selective cannabinoids will need to be discovered so that they can trigger the right cannabinoid receptors.
In rodent hippocampal regions cannabinoid receptor triggerers induced both glutamatergic synaptic signalling allowed by decreasing magnesium concentrations, which entices the whole system of brain molecules in the network and glutamatergic synaptics enticed by the current triggering the presynaptic neuron. These impacts were transparently controlled by cannabinoid receptors, as suggested by pharmacological benchmark: The triggers were strong subnanomolar doses induced neuro-signalling pattern. The inducing was stereoselective, supposedly.
The chemical compounds were different in effectiveness in the central nervous system. The category of strength was on par with earlier reported amounts at cannabinoid receptor sites. This research is promising in that it describes how cannabinoids can boost the effectiveness in the brains of rats. Further studies in humans will be needed to see if major cannabinoids can do the same as it has in the rats.